Description
The excision repair cross-complementation group 1 (ERCC1) gene encodes a protein
essential for nucleotide excision repair and inter-strand crosslink repair of DNA.
Chemotherapeutic agents that induce DNA damage, such as cisplatin, are frequently
employed for non-small cell lung carcinoma and other advanced cancers; however,
they exhibit significant resistance and considerable adverse effects . Resistance to
platinum-based chemotherapy is associated with increased levels of ERCC1-XPF
nuclease, suggesting that ERCC1 may serve as a possible predictive diagnostic
biomarker . The expression of ERCC1 may possess prognostic significance in lung,
colorectal, head & neck, bladder, breast, and cervical malignancies .
While clone 8F1 has been conventionally employed in immunohistochemistry to
identify ERCC1 expression, it has been discovered that 8F1 cross-reacts with PCYT1A,
an unrelated nuclear membrane protein. Clone 4F9 exhibits no cross-reactivity, hence
ensuring enhanced specificity for ERCC1 expression.
Specifications
| Intended Use | RUO |
|---|---|
| Format | Concentrate |
| Volume | 0.1 ml, 0.5 ml |
| Source | Mouse Monoclonal |
| Clone | 4F9 |
| Isotype | IgG1 |
| Antigen | Protein expressed in 293T cell transfected with human ERCC1 expression vector |
| Localization | Nuclear, cytoplasmic |
| Positive Control | Prostate or prostate cancer |
